BR112019006194A2 - composições que compreendem um ligante de ligação ao receptor de canabinóides - Google Patents

composições que compreendem um ligante de ligação ao receptor de canabinóides

Info

Publication number
BR112019006194A2
BR112019006194A2 BR112019006194A BR112019006194A BR112019006194A2 BR 112019006194 A2 BR112019006194 A2 BR 112019006194A2 BR 112019006194 A BR112019006194 A BR 112019006194A BR 112019006194 A BR112019006194 A BR 112019006194A BR 112019006194 A2 BR112019006194 A2 BR 112019006194A2
Authority
BR
Brazil
Prior art keywords
receptor binding
cannabinoid receptor
compositions
binding binder
binder
Prior art date
Application number
BR112019006194A
Other languages
English (en)
Portuguese (pt)
Inventor
Günther Bernhard
Löscher Frank
Steven Philipp
Krösser Son­Ja
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of BR112019006194A2 publication Critical patent/BR112019006194A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112019006194A 2016-09-28 2017-09-27 composições que compreendem um ligante de ligação ao receptor de canabinóides BR112019006194A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191194 2016-09-28
EP17168172 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (1)

Publication Number Publication Date
BR112019006194A2 true BR112019006194A2 (pt) 2019-06-18

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019006194A BR112019006194A2 (pt) 2016-09-28 2017-09-27 composições que compreendem um ligante de ligação ao receptor de canabinóides

Country Status (10)

Country Link
US (1) US20190343793A1 (enExample)
EP (2) EP3698785A1 (enExample)
JP (1) JP2019534867A (enExample)
KR (1) KR20190060787A (enExample)
CN (1) CN109803650A (enExample)
AU (1) AU2017333420A1 (enExample)
BR (1) BR112019006194A2 (enExample)
CA (1) CA3036313A1 (enExample)
MX (1) MX2019003544A (enExample)
WO (1) WO2018060282A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
MX360469B (es) 2012-09-12 2018-11-05 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
DE202013012753U1 (de) 2012-09-12 2019-03-04 Novaliq Gmbh Zusammensetzungen semifluorierter Alkane zur Verwendung in der Behandlung von Keratoconjunctivitis Sicca
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
ES2953837T3 (es) 2015-09-30 2023-11-16 Novaliq Gmbh 2-perfluorobutil pentano para administración oftálmica
CN120884568A (zh) 2015-09-30 2025-11-04 诺瓦利克有限责任公司 半氟化化合物和其组合物
AU2017260444B2 (en) 2016-05-03 2019-05-09 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system and methods of use
EP3442480B1 (en) 2016-06-23 2019-10-02 Novaliq GmbH Topical administration method
US11684589B2 (en) 2016-09-22 2023-06-27 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
US10732712B2 (en) * 2016-12-27 2020-08-04 Facebook Technologies, Llc Large scale integration of haptic devices
MX388460B (es) 2017-04-21 2025-03-20 Dermaliq Therapeutics Inc Composiciones de yodo.
CN110650734B (zh) 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
IL273531B2 (en) 2017-09-27 2024-05-01 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
EP3706843B1 (en) 2017-11-08 2024-06-26 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
JP7665519B2 (ja) * 2019-02-01 2025-04-21 アルコン インコーポレイティド 近視を治療するための化合物、組成物及び医薬組成物
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
WO2021044045A1 (en) 2019-09-06 2021-03-11 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
US12576039B2 (en) 2020-05-18 2026-03-17 Max Biology Co. Ltd. Lipid-polymer compositions and methods of use
US20230363441A1 (en) * 2020-09-24 2023-11-16 Nicoventures Trading Limited Formulation
JP2023543925A (ja) * 2020-10-05 2023-10-18 マックス バイオロジー カンパニー リミテッド カンナビノイド含有組成物及び疾患の処置及び予防のための使用
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
WO2022169788A1 (en) 2021-02-03 2022-08-11 Ads Therapeutics Llc Topical ophthalmological compositions
ES3040366T3 (en) 2021-06-22 2025-10-30 Pneuma Respiratory Inc Droplet delivery device with push ejection
WO2023064477A1 (en) * 2021-10-13 2023-04-20 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
US12161795B2 (en) 2022-07-18 2024-12-10 Pneuma Respiratory, Inc. Small step size and high resolution aerosol generation system and method
WO2026037894A1 (en) * 2024-08-15 2026-02-19 Dermaliq Therapeutics, Inc. Semifluorinated alkane compositions for cleaning the skin
WO2026047389A1 (en) * 2024-08-30 2026-03-05 Vicadia Lda Topical delivery of cannabinoid-based formulations for ocular allergy and inflammation in ophthalmic diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US20080112895A1 (en) 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
WO2010051541A2 (en) 2008-10-31 2010-05-06 The University Of Mississippi Compositions containing delta-9-thc-amino acid esters and process of preparation
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
DE202013012753U1 (de) * 2012-09-12 2019-03-04 Novaliq Gmbh Zusammensetzungen semifluorierter Alkane zur Verwendung in der Behandlung von Keratoconjunctivitis Sicca
MX360469B (es) * 2012-09-12 2018-11-05 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
CN106061490A (zh) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
EP3071193B1 (en) 2013-11-20 2020-01-08 Panag Pharma Inc. Compositions and methods for treatment of ocular inflammation and pain
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Also Published As

Publication number Publication date
CA3036313A1 (en) 2018-04-05
US20190343793A1 (en) 2019-11-14
JP2019534867A (ja) 2019-12-05
AU2017333420A1 (en) 2019-04-04
EP3698785A1 (en) 2020-08-26
EP3518921B1 (en) 2021-08-11
CN109803650A (zh) 2019-05-24
WO2018060282A1 (en) 2018-04-05
EP3518921A1 (en) 2019-08-07
KR20190060787A (ko) 2019-06-03
MX2019003544A (es) 2019-09-19

Similar Documents

Publication Publication Date Title
BR112019006194A2 (pt) composições que compreendem um ligante de ligação ao receptor de canabinóides
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
CL2019000266A1 (es) Composición de cannabis.
MX395149B (es) Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
DOP2016000125A (es) MODULADORES DE ROR GAMMA (RORy)
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
MX2022015258A (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
CR20180175A (es) Anticuerpos anti-cd19 humano con alta afinidad
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112016002233A2 (pt) composições de adoçante
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CL2016000925A1 (es) Inhibidores de bromodominio
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
BR112019006642A2 (pt) antagonistas multiméricos de e-selectina altamente potentes
CL2019003430A1 (es) Tratamiento conjunto antineoplásico.
BR112016017010A2 (pt) Anticorpo monoclonal de fator antitecido
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112015026289A2 (pt) selantes adesivos contendo alcoxissilila com viscosidade intrinsecamente reduzida
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
CO2018005753A2 (es) Composición hemostática

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2741 DE 18/07/2023.